Vnitr Lek 2006, 52(9):765-767

Monitorování glykemie u kriticky nemocných pacientů - editorial

J. Rybka
Diabetologické centrum Interní kliniky IPVZ, WHO-CC, Krajská nemocnice T. Bati, a.s., Zlín, přednosta prim. MUDr. Ivo Oral, CSc.

Received: May 24, 2006; Published: September 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rybka J. Monitorování glykemie u kriticky nemocných pacientů - editorial. Vnitr Lek. 2006;52(9):765-767.
Download citation

References

  1. Bartnik M, Rydém L, Ferrari R et al. On behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004; 25: 1880-1890. Go to original source... Go to PubMed...
  2. Creager MA, Lüscher TF, Cosentino F et al. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: Part I. Circulation 2003; 108: 1527-1532. Go to original source... Go to PubMed...
  3. DeBacker G, Ambrosini E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10. Go to original source... Go to PubMed...
  4. Festa A, D'Agostino R jr, Howard G et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47. Go to original source... Go to PubMed...
  5. Haffner SM, Letho S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl Med 1998; 339: 229-234. Go to original source... Go to PubMed...
  6. Hanley AJ, Karter AJ, Festa A et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 2642-2647. Go to original source... Go to PubMed...
  7. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79: 992-1000. Go to original source... Go to PubMed...
  8. Křemen J, Anderlová K, Bláha J et al. Mikrodialýza tukové tkáně a její využití v klinickém výzkumu a praxi. Prakt Lék 2005; 85: 434-436.
  9. Lüscher TF, Creager MA, Beckman JA et al. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003; 108: 1655-1661. Go to original source... Go to PubMed...
  10. Mackenzie I, Ingle S, Zaidi S et al. Tight glycaemic control: a survey of intensive care practice in large English hospitals. Intensive Care Med 2005; 31: 1136. Go to original source... Go to PubMed...
  11. Malmberg K, Norhammar A, Wedel H et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999; 99: 2626-2632. Go to original source... Go to PubMed...
  12. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-2771. Go to original source... Go to PubMed...
  13. Schultz MJ, Spronk PE, Moeniralam HS. Tight glycaemic control: a survey of intensive care practice in the Netherlands. Intensive Care Med 2006; 32: 618-619. Go to original source... Go to PubMed...
  14. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med, 2001; 345: 1359-1367. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.